Picture of Lite Strategy logo

LITS Lite Strategy Share Price

0.000.00%
us flag iconLast trade - 00:00
FinancialsAdventurousMicro CapNeutral

Momentum

Relative Strength (%)
1m-25.47%
3m-50.25%
6m-81.22%
1yr-67.21%
Volume Change (%)
10d/3m-36.97%
Price vs... (%)
52w High-88.22%
50d MA-27.67%
200d MA-59.3%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-11.44%
Return on Equity-16.88%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202630th Jun 2027
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2026 / 2027

Blurred out image of Lite Strategy EPS forecast chart

Profile Summary

Lite Strategy, Inc., formerly MEI Pharma, Inc., is a Litecoin treasury company. The Company accumulates pure LTC through active treasury management and concentrates holdings per share as the ultimate metric of shareholder value. It is a clinical-stage pharmaceutical company focused on the development of differentiated cancer therapies intended to improve outcomes for patients. Its approach to oncology drug development is to evaluate its drug candidates in combination with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs. The portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3Kd inhibitor. Voruciclib is a selective orally administered CDK9 inhibitor with potential to treat both hematological malignancies and solid tumors. Voruciclib, a selective orally administered inhibitor of CDK9, is in clinical development for acute myeloid leukemia.

Directors

Last Annual
June 30th, 2025
Last Interim
September 30th, 2025
Incorporated
December 1st, 2000
Public Since
December 18th, 2003
No. of Shareholders
315
No. of Employees
4
Sector
Investment Banking & Investment Services
Industry
Financials
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
36,769,677

LITS Share Price Performance

Upcoming Events for LITS

Lite Strategy Inc Annual Shareholders Meeting

Q2 2026 Lite Strategy Inc Earnings Release

Q3 2026 Lite Strategy Inc Earnings Release

Similar to LITS

Picture of Aether Holdings logo

Aether Holdings

us flag iconNASDAQ Capital Market

Picture of Agora Digital Holdings logo

Agora Digital Holdings

us flag iconNASDAQ Capital Market

Picture of Aixcrypto Holdings logo

Aixcrypto Holdings

us flag iconNASDAQ Capital Market

Picture of AlphaTON Capital logo

AlphaTON Capital

us flag iconNASDAQ Capital Market

Picture of ALT5 Sigma logo

ALT5 Sigma

us flag iconNASDAQ Capital Market

FAQ